Sampre Nutritions Ltd has announced a significant move towards expanding its global footprint. The company’s Board of Directors approved the issuance of foreign currency convertible bonds (FCCBs) worth ₹355 crore ($4 million). These funds will primarily be used to strengthen Sampre’s presence in emerging markets, particularly Egypt and Liberia, with the aim of capturing new opportunities in the FMCG sector.
The company plans to issue 400 FCCBs, each valued at $1,00,000, aggregating to $4 million (₹355 crore). These bonds will be available for subscription from October 10, 2025, to October 15, 2025, on the Afrinex Exchange Mauritius. Sampre Nutritions has entered into an agreement with ARIES Capital Ltd. to manage the listing and underwriting of the issue.
The funds from the FCCB issue are earmarked for expanding Sampre Nutrition's presence in high-growth international markets, particularly in Egypt and Liberia. These emerging markets are expected to offer significant potential for the company's confectionery and FMCG products, allowing Sampre to diversify its revenue streams and enhance its global reach.
In line with its expansion plans, Sampre Nutritions also approved a bonus issue and stock split during a board meeting on September 19, 2025. The company will split each equity share of ₹10 into two shares of ₹5 each and issue one bonus share for every fully paid-up equity share. This initiative will require ₹21.55 crore, sourced from the securities premium account, with bonus shares credited by December 19, 2025.
Moreover, Sampre has recently converted 550,000 warrants into equity shares, further solidifying the promoter group's stake in the company. The conversion was carried out following shareholder approval and in alignment with the company’s strategy to enhance its capital base.
Read More: Sampre Nutritions Allots 2.9 Lakh Equity Shares To Promoter on Warrant Conversion; Share Price in Focus!
The company has also entered into significant agreements with Tolaram Wellness Ltd. (Nigeria) and Rama Exports, which will contribute to a projected business of ₹45 crore over the next three years. This strategic alignment is expected to drive further growth in the nutraceutical and food sectors.
For Q1FY26, Sampre reported impressive financial growth, with revenues up by 141% YoY to ₹10.87 crore and a net profit surge of 615% YoY, reaching ₹70.76 lakh. These results reflect the company’s strong operational performance and ongoing expansion efforts.
On October 6, 2025, Sampre Nutritions share price opened at ₹128.65 on BSE, above the previous close of ₹126.15. The stock is trading at ₹128.65 as of 11:17 AM. The stock registered a moderate gain of 1.98% hitting the upper circuit.
Over the past week, it has moved up by 8.19%, over the past month, it has moved up by 48.44%, and over the past 3 months, it has moved up by 245.37%.
The approval of the FCCB issue by Sampre Nutritions marks a major step in its global expansion strategy. By targeting high-potential markets like Egypt and Liberia, the company aims to strengthen its position in the FMCG sector, diversify its revenue streams, and support its continued growth in international markets. Along with other corporate developments, Sampre is positioning itself for a promising future.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in securities are subject to market risks. Read all related documents carefully before investing.
Published on: Oct 6, 2025, 12:51 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
